Literature DB >> 3924871

Enhancement of antitumor effect of cytotoxic agents by bestatin.

F Abe, K Shibuya, J Ashizawa, K Takahashi, H Horinishi, A Matsuda, M Ishizuka, T Takeuchi, H Umezawa.   

Abstract

Bestatin enhanced the antitumor effects of mitomycin C, 5-fluorouracil and cis-dichlorodiammineplatinum against a syngeneic solid tumor of colon adenocarcinoma 26 in BALB/c mice. The enhancement was dependent on administration schedule. Bestatin administration after treatment with the cytotoxic agents was more effective than that made before the treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924871     DOI: 10.7164/antibiotics.38.411

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  5 in total

1.  Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases.

Authors:  F Abe; G Alvord; M Koyama; A Matsuda; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice.

Authors:  F Abe; A Matsuda; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.

Authors:  F Abe; M Schneider; P L Black; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 4.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

5.  In Vivo Molecular Imaging of the Efficacy of Aminopeptidase N (APN/CD13) Receptor Inhibitor Treatment on Experimental Tumors Using 68Ga-NODAGA-c(NGR) Peptide.

Authors:  Adrienn Kis; Noémi Dénes; Judit P Szabó; Viktória Arató; Lívia Beke; Orsolya Matolay; Kata Nóra Enyedi; Gábor Méhes; Gábor Mező; Péter Bai; István Kertész; György Trencsényi
Journal:  Biomed Res Int       Date:  2021-03-10       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.